Los Angeles County

1 Los Angeles County Department of Public Health 2/28/22 COVID-19 Vaccine Eligibility: Providers Los Angeles County COVID-19 VACCINES: Provider Summary Table - 1 of 2 - Use these tables to help determine when to give COVID-19 vaccine doses based on patient age, primary series, and/or if the patient is immunocompromised. Refer to CDC Clinical Considerations for Use of COVID-19 Vaccines for detailed guidance. The most current version of these tables are available online. IMMUNOCOMPETENT PATIENTS Vaccine Dose Patient Age 5-11 12-17 18+ Pfizer1/Comirnaty (mRNA vaccine) Primary 2-dose series2 (3-8 weeks apart3) Booster dose2,4 (at least 5 months after 2nd dose) Any vaccine; mRNA preferred Moderna5/Spikevax (mRNA vaccine) Primary 2-dose series2 (4-8 weeks apart3) Booster dose2,4 (at least 5 months after 2nd dose) Any vaccine.

2 MRNA preferred Johnson & Johnson (J&J)/Janssen Note: J&J vaccine is an alternative vaccine option for persons in certain situations Primary single dose2 Booster dose2,4 (at least 2 months after 2nd dose) Any vaccine; mRNA preferred Fully Vaccinated with non-FDA-authorized/ approved series6 Booster dose2,4 (at least 5 months after primary series) Only Pfizer authorized Only mRNA authorized Footnotes (1) Pfizer has two different formulations. Persons age 12 and older receive 30 g dose in mL (purple cap, which needs diluent, or gray cap, which does not require diluent).

3 Age 5-11: 10 g dose in mL (orange cap). (2) People with known current SARS-CoV-2 infection should defer vaccination until they have recovered from the acute illness (if symptoms were present) and they have discontinued isolation. For individuals diagnosed with MIS-C/MIS-A, refer to Clinical Considerations. (3) Timing of 2nd dose. An 8-week interval may be optimal for some people aged 12-64, especially for males 12-39 years of age. A longer interval may improve vaccine effectiveness and lower the risk of myocarditis. The shorter 3-week (Pfizer) and 4-week (Moderna) are recommended for children age 11 and younger, adults age 65 years and older, and others who need rapid protection during times of high community transmission and/or are at risk of severe disease.

4 (4) Booster doses. Only Pfizer is authorized as a booster in adolescents age 12-17. No booster is authorized for children 5-11. Persons ages 18 and older can choose between any of the three FDA-authorized/approved COVID-19 vaccines; however, mRNA vaccines are preferred. Moderna booster is a half dose (50 g in mL). Only the mRNA vaccines (Pfizer/Moderna) are authorized as a booster for people who did not receive an FDA-authorized/approved COVID-19 vaccine series. (5) Moderna has two dose volumes. The full dose (100 g in mL) is authorized for the primary series. A half doce (50 g in mL) is authorized for booster doses. (6) Persons who are considered fully vaccinated with a non-FDA-authorized/approved series include those who completed a WHO-EUL COVID-19 vaccine series, those who completed a heterologous (mix and match) series composed of any combination of FDA-approved, FDA-authorized, or WHO-EUL COVID-19 vaccines, and those who have received the full series of an "active" (not placebo) COVID-19 vaccine candidate for which vaccine efficacy has been independently confirmed ( , by a data and safety monitoring board).

5 Los Angeles County Department of Public Health 2/28/22 COVID-19 Vaccine Eligibility: Providers Los Angeles County COVID-19 VACCINES: Provider Summary Table Footnotes (1) Pfizer has two different formulations. Persons age 12 and older receive 30 g dose in mL (purple cap, which needs diluent, or gray cap, which does not require dilution). Age 5-11: 10 g dose in mL (orange cap). (2) People with known current SARS-CoV-2 infection should defer vaccination until they have recovered from the acute illness (if symptoms were present) and they have discontinued isolation. For individuals diagnosed with MIS-C/MIS-A, refer to Clinical Considerations. (3) Additional primary doses. A 3-dose primary series is recommended for mRNA vaccines.

6 Persons who received a single J&J dose should receive an additional (2nd) mRNA vaccine dose. If Moderna COVID-19 vaccine is used for the additional dose, administer a full 100 g ( mL) dose. Only mRNA vaccines (Pfizer/Moderna) are authorized as additional doses for people who did not receive an FDA-authorized/ approved COVID-19 vaccine series. (4) Moderna has two dose volumes. The full dose (100 g in mL) is authorized for the primary series and for additional doses. A half dose (50 g in mL) is authorized for the booster dose. (5) Booster doses. Only Pfizer is authorized as booster in adolescents age 12-17. No booster is authorized for children 5-11. Persons ages 18 and older can choose between any of the three FDA-authorized/approved COVID-19 vaccines; however, mRNA vaccines are preferred.

7 Moderna booster is a half dose (50 g in mL), even for immunocompromised persons. Only the mRNA vaccines (Pfizer/Moderna) are authorized as a booster for people who did not receive an FDA-authorized/approved COVID-19 vaccine series. (6) Persons who are considered fully vaccinated with a non-FDA-authorized/approved series include those who completed a WHO-EUL COVID-19 vaccine series, those who completed a heterologous (mix and match) series composed of any combination of FDA-approved, FDA-authorized, or WHO-EUL COVID-19 vaccines, and those who have received the full series of an "active" (not placebo) COVID-19 vaccine candidate for which vaccine efficacy has been independently confirmed ( , by a data and safety monitoring board).

8 For more information, see CDC Clinical Considerations for Use of COVID-19 Vaccines MODERATELY OR SEVERELY IMMUNOCOMPROMISED PATIENTS Vaccine Dose Patient Age 5-11 12-17 18+ Pfizer1/Comirnaty (mRNA vaccine) Primary 2-dose series2 (21 days apart) Additional primary (3rd) dose2,3 (at least 28 days after 2nd Pfizer dose) Booster dose2,5 (at least 3 months after 3rd dose) Any vaccine; mRNA preferred Moderna4/Spikevax (mRNA vaccine) Primary 2-dose series2 (28 days apart) Additional primary (3rd) dose2,3 (at least 28 days after 2nd Moderna dose) Booster dose2,5 (at least 3 months after 3rd dose) Any vaccine.

9 MRNA preferred Johnson & Johnson (J&J)/Janssen Note: J&J vaccine is an alternative vaccine option for persons in certain situations Primary single dose2 Additional (2nd) dose2,3 (at least 28 days after single J&J dose) Only mRNA authorized Booster dose2,5 (at least 2 months after 2nd dose) Any vaccine; mRNA preferred See Appendix B: Guidance for People who are Immunocompromised and Vaccinated with J&J Fully Vaccinated with non-FDA-authorized/ approved series6 Additional (3rd) dose2,3 (at least 28 days after 2nd dose) Only Pfizer authorized Only mRNA authorized Booster dose2,5 (at least 3 months after 3rd dose) Only Pfizer authorized Only mRNA authorized - 2 of 2.